Is Office-based Management of Intermediate-risk Low-grade Non-muscle-invasive Bladder Cancer Ready For Prime Time?
Eur Urol
.
2023 Feb;83(2):131-132.
doi: 10.1016/j.eururo.2022.09.001.
Epub 2022 Sep 22.
Authors
Jacob Taylor
1
,
Yair Lotan
2
Affiliations
1
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
2
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: yair.lotan@utsouthwestern.edu.
PMID:
36153249
DOI:
10.1016/j.eururo.2022.09.001
No abstract available
Publication types
Editorial
Comment
MeSH terms
Administration, Intravesical
Humans
Neoplasm Invasiveness
Neoplasm Recurrence, Local
Non-Muscle Invasive Bladder Neoplasms*
Urinary Bladder Neoplasms* / drug therapy